Crossmark Global Holdings, Inc. Innoviva, Inc. Transaction History

Crossmark Global Holdings, Inc.

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 10, 2022	SELL	$15.91 - $18.72 $485,891 - $571,708	-30,540 Closed	0 $0
Q3 2021 Oct 21, 2021	BUY	$13.06 - $17.24 $398,852 - $526,509	30,540 New	30,540 $510,000
Q3 2021 Oct 13, 2021	SELL	$13.06 - $17.24 $399,897 - $527,888	-30,620 Closed	0 $0
Q2 2021 Jul 21, 2021	BUY	$11.45 - $13.96 $1,717 - $2,094	150 Added 0.49%	30,620 $411,000
Q4 2020 Jan 14, 2021	BUY	$9.33 - $12.48 $62,790 - $83,990	6,730 Added 28.35%	30,470 $378,000
Q2 2020 Aug 14, 2020	BUY	$11.49 - $15.26 $7,928 - $10,529	690 Added 2.99%	23,740 $332,000
Q4 2019 Feb 06, 2020	BUY	$10.28 - $14.38 $102 - $143	10 Added 0.04%	23,050 $326,000
Q3 2019 Oct 09, 2019	SELL	$10.05 - $14.55 $1,708 - $2,473	-170 Reduced 0.73%	23,040 $243,000
Q2 2019 Jul 09, 2019	SELL	$13.1 - $14.95 $16,794 - $19,165	-1,282 Reduced 5.23%	23,210 $338,000
Q1 2019 May 02, 2019	SELL	$13.69 - $20.06 $2,464 - $3,610	-180 Reduced 0.73%	24,492 $344,000
Q4 2018 Jan 31, 2019	SELL	$13.96 - $18.26 $186,924 - $244,501	-13,390 Reduced 35.18%	24,672 $431,000
Q3 2018 Nov 08, 2018	BUY	$13.63 - $15.7 $7,223 - $8,321	530 Added 1.41%	38,062 $580,000
Q2 2018 Jul 31, 2018	SELL	$13.44 - $17.59 $1,881 - $2,462	-140 Reduced 0.37%	37,532 $518,000
Q1 2018 Apr 16, 2018	SELL	$13.8 - $16.99 $28,317 - $34,863	-2,052 Reduced 5.17%	37,672 $628,000
Q4 2017 Feb 05, 2018	BUY	$11.73 - $14.75 $23,366 - $29,382	1,992 Added 5.28%	39,724 $564,000
Q3 2016 Oct 25, 2017	BUY	N/A	37,732	37,732 $533,000

229

79.2M

37.6K

300

Ticker INVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,706,000
Market Cap $1.33B
Description
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...

Get notified when there are updates to the investment portfolio of Crossmark Global Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Crossmark Global Holdings, Inc. with notifications on news.